The FLT3 gene encodes a transmembrane receptor of the tyrosine kinase group. Binding of specific ligand to the FLT3 receptor leads to production of the proteins that change proliferative characteristics of the cells and inhibit apoptosis. FLT3 gene mutations are observed in 20% - 30% of patients with acute myeloid leukemia (AML). The highest frequency of mutations is observed in adult patients with a normal karyotype, as well as in patients with acute promyelocytic leukemia. Intra-tandem duplications (ITD) in exons 14 or 15 represent the most common FLT3 mutations. Presence of the FLT3 ITD mutation predicts unfavorable course of the disease. The second most common mutation is a point substitution in the aspartate codon (D835) of FLT3 kinase domain. D835 mutation has been identified in approximately 7% of AML cases, but the prognostic value of this mutation has not yet been determined. It is believed that both types of FLT3 mutations lead to constitutive (permanent, regardless of regulatory factors) activation of FLT3. Detection of FLT3 gene mutation in AML is clinically appropriate, both to assess the prognosis of the disease and to prove targeted therapy with FLT3 inhibitors, which demonstrate high efficiency in the treatment of AML relapses.
Reagent kit for detecting mutations in the FLT3 gene (ITD, D835) by fragment analysis.
Available product:
FLT3 MutaPrime FA Kit, 24 tests Cat.No IG-FA-4-24
Additiional reagents:
Column DNA Kit, 100 extr. Cat.No IG-CDK-100
Erythrocyte Lysis Solution reagent Cat.No IG-TRL-100
Price: on request
Reagents are for research use only (RUO)